

# Answering the Call: Inpatient Vaccination for SARS-CoV2 Infection in an Academic Hospital

Benjamin Albrecht, PharmD, BCIDP<sup>1</sup>; Sarah Green, PharmD, BCPS, BCIDP, AAHIVP<sup>1</sup>; Terry Thompson<sup>1</sup>; Peter Moran, PharmD, BCCCP<sup>1</sup>; Morgan E. Corkish, PharmD<sup>1</sup>; Carrie Tilton, PharmD, BCPS<sup>1</sup>; Ashley Rizzo, PharmD<sup>3</sup>; Michael Hurtik, PharmD<sup>1</sup>; Chidozie Ukpabi, PharmD<sup>1</sup>; Litsa Vastakis, PharmD<sup>1</sup>; Othman Mohammed, PharmD<sup>1</sup>; Kristen McGraw, PharmD, MBA, BCPS<sup>1</sup>; Nicole Metzger, PharmD, BCPS<sup>1</sup>; Phillip Mohorn, PharmD, BCCCP<sup>1</sup>; Christele Francois, PharmD, BCPS<sup>1</sup>; Mary Brown<sup>1</sup>; Mary Elizabeth Sexton, MD, MSc<sup>2</sup>


1. Department of Pharmacy, Emory University Hospital, Atlanta, GA 2. Division of Infectious Diseases, Emory University SOM, Atlanta, GA 3. Mercer University College of Pharmacy, Atlanta, GA

## Introduction

- The CDC has reported that 787 patients per 100,000 people in the United States have been hospitalized due to COVID-19, with ~20% of those patients requiring intensive care<sup>1</sup>
- Despite being effective and widely available, primary series and booster vaccine administration rates have remained suboptimal<sup>1</sup>
- Vaccine administration has been complicated by changing schedule recommendations, packaging in multi-dose vials, provider and patient hesitancy, and local and federal reporting requirements<sup>2</sup>
- Other institutions have demonstrated success with inpatient SARS-CoV2 vaccine programs utilizing a single vaccine only<sup>3,4</sup>
- Emory University Hospital (EUH) offered all authorized or approved SARS-CoV2 vaccines to admitted or emergency department (ED) patients through an integrated, decentralized model beginning in August 2021

## Methods


- EUH initiated a hospital-based (inpatient or ED visit) SARS-CoV2 vaccination campaign utilizing the following procedure:



- Vaccine candidates were identified through provider interview or patient request, with patients in procedural areas, critically-ill or recently and significantly immunocompromised patients, and those with active COVID-19 isolation status excluded
- Vaccines provided included the authorized Pfizer-BioNTech and Comirnaty® (Pfizer), authorized Moderna and Spikevax® (Moderna), and Janssen (J&J) SARS-CoV2 vaccine formulations; they were delivered by pharmacy at a set time daily to limit waste
- A retrospective review of vaccine administration rates within EUH inpatient and ED areas from 8/2021 through 3/2022 was conducted

## Results

### COVID-19 Inpatient Vaccines at EUH



DOT: days of therapy (# of Vaccine Doses)


Vaccine and Dose	Total Ordered	Total Administered	Completion
J&J 1st	1	1	100%
J&J Dose Unknown	13	8	62%
Moderna 1st	47	44	94%
Moderna 2nd	20	18	90%
Moderna 3rd	13	13	100%
Moderna Dose Unknown	16	0	0%
Moderna Booster	51	34	67%
Pfizer 1st	87	76	87%
Pfizer 2nd	27	24	89%
Pfizer 3rd	39	39	100%
Pfizer Booster	12	12	100%
Pfizer Dose Unknown	37	3	8%
<b>All Vaccines</b>	<b>363</b>	<b>272</b>	<b>75%</b>

Vaccine and Dose	Total Ordered	Total Administered	Completion
Moderna Primary	96	75	78%
Pfizer Primary	190	142	75%
<b>Total Primary</b>	<b>286</b>	<b>217</b>	<b>76%</b>
Moderna Booster	51	34	67%
Pfizer Booster	12	12	100%
<b>Total Booster</b>	<b>63</b>	<b>46</b>	<b>73%</b>

## Results

- From 8/2021 to 3/2022, a total of 13362 patients were admitted or visited the ED, suggesting that **at least 2% of patients received at least 1 SARS-CoV2 vaccine** during that timeframe
- Vaccines were primarily ordered by hospitalists (37%), followed by solid organ transplant (SOT) specialists (10%)

### Administered Vaccines by Ordering Provider Specialty



## Summary and Conclusions

- SARS-CoV2 vaccination in hospitalized patients is possible with interdisciplinary support, with limitations of provider/patient interest and a need for waste minimization
- A wide range of provider specialties are willing to participate in SARS-CoV2 vaccination in patients admitted to the hospital

## References

- Centers for Disease Control and Prevention. COVID Data Tracker. CDC; 2022, May 02.
- Tenforde MW, et al. MMWR Morb Mortal Wkly Rep 2022;71:459-465.
- Berger, Rebecca E., et al. *NEJM Catalyst Innovations in Care Delivery* 2.10 (2021).
- Martinot, Martin, et al. *Clinical Microbiology and Infection* (2022).